Tilray Brands (TLRY) Receivables - Net (2017 - 2026)
Tilray Brands' (TLRY) quarterly Receivables - Net came in at $189.2 million in Q2 2026, up 55.71% YoY from $121.5 million in Q2 2025, and up 59.81% on a QoQ basis from $118.4 million in Q1 2026.
Tilray Brands (TLRY) Receivables - Net (2017 - 2026) Analysis & Trends
Tilray Brands (TLRY) has 10 years of Receivables - Net data on file, last reported at $189.2 million in Q2 2026.
- Quarterly Receivables - Net rose 55.71% year-over-year to $189.2 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $189.2 million (up 55.71% YoY) and the FY2026 annual result came in at $189.2 million, up 55.71% from the prior year.
- Receivables - Net climbed to $189.2 million in Q2 2026, from $118.4 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $189.2 million in Q2 2026 to a low of $78.3 million in Q1 2023.
- A 5-year average of $103.7 million and a median of $98.3 million in 2022 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2023 — Receivables - Net retreated 16.54% — and 2026, when it jumped 55.71%.
- Tracing TLRY's Receivables - Net over 5 years: stood at $89.7 million in 2022, then grew by 0.99% to $90.6 million in 2023, then grew by 24.44% to $112.7 million in 2024, then retreated by 3.25% to $109.1 million in 2025, then jumped by 73.44% to $189.2 million in 2026.
- The last three Receivables - Net figures came in at $189.2 million (Q2 2026), $118.4 million (Q1 2026), and $109.1 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Tilray Brands | 513.87 Mn | 279.24 Mn | 90.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 189.17 Mn |
| May 31, 2026 | 189.17 Mn |
| Feb 28, 2026 | 118.37 Mn |
| Feb 28, 2026 | 118.37 Mn |
| Nov 30, 2025 | 109.07 Mn |
| Nov 30, 2025 | 109.07 Mn |
| Aug 31, 2025 | 107.08 Mn |
| Aug 31, 2025 | 107.08 Mn |
| May 31, 2025 | 121.49 Mn |
| May 31, 2025 | 121.49 Mn |
| Nov 30, 2024 | 112.74 Mn |
| Nov 30, 2024 | 112.74 Mn |
| Aug 31, 2024 | 104.04 Mn |
| Aug 31, 2024 | 104.04 Mn |
| May 31, 2024 | 101.70 Mn |
| May 31, 2024 | 101.70 Mn |
| Feb 29, 2024 | 89.54 Mn |
| Feb 29, 2024 | 89.54 Mn |
| Nov 30, 2023 | 90.60 Mn |
| Nov 30, 2023 | 90.60 Mn |